Use of Palivizumab Prophylaxis to Prevent Hospitalization from Severe RSV Infection
The Office of MaineCare Services (OMS), in coordination with their Pharmacy Benefits Manager Change Healthcare (CHC), review data from the National Respiratory and Enteric Virus Surveillance System (NREVSS) to track the epidemic season for Respiratory Syncytial Virus (RSV). Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by RSV in infants. Peak RSV activity typically occurs between November and March.